A Preliminary Study of the Effectiveness and Tolerability of Aripiprazole in Bipolar Depression
Bipolar Depression
About this trial
This is an interventional treatment trial for Bipolar Depression focused on measuring Adults, Bipolar Depression, Bipolar Disorder, Bipolar I, Bipolar II, Depression
Eligibility Criteria
Inclusion Criteria: subjects must have bipolar I, II or NOS disorder as defined by DSM-IV-TR; must have clinical significant depressive symptoms and have failed one or more mood stabilizer trials; may or may not be receiving antimanic or mood stabilizing medications; subjects or legally authorized representative must sign the Informed Consent document after the nature of the trial has been fully explained; if female, subjects must be postmenopausal, surgically incapable of childbearing or practicing medically acceptable effective method(s) of contraception. Exclusion Criteria: subjects who do not have bipolar disorder by DSM-IV criteria; subjects with current DSM-IV Axis I diagnosis of delirium, dementia, amnesia or other cognitive disorders or a psychotic disorder; subjects with serious general medical illness; subjects who are allergic to or have demonstrated hypersensitivity to aripiprazole; women who are pregnant or nursing; subjects who have received an experimental drug or used an experimental device within 30 days; subjects who have a history of neurologic malignant syndrome.
Sites / Locations
- University of Cincinnati Medical Center